Gland PharmaNSE:GLAND +5.14%83 Days Inventory is 269.10 as of Mar. 2026, which is 5% below its 10-year median of 283.29. GuruFocus rates NSE:GLAND with a GF Score™ of 83/100 and a GF Value™ of ₹2,129.62 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 917 Drug Manufacturers companies, Gland Pharma ranks worse than 81.9% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Gland Pharma's Average Total Inventories for the
three
months ended in Mar. 2026 was ₹17,439 Mil. Gland Pharma's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₹5,913 Mil.
Hence, Gland Pharma's Days Inventory for the
three
months ended in Mar. 2026 was 269.10.
The historical rank and industry rank for Gland Pharma's Days Inventory or its related term are showing as below:
NSE:GLAND'
s Days Inventory Range Over the Past 10 Years
Min: 212.92 Med: 283.29 Max: 339.02
Current: 284.39
During the past 9 years, Gland Pharma's highest Days Inventory was 339.02. The lowest was 212.92. And the median was 283.29.
NSE:GLAND's Days Inventory is ranked worse than 81.9% of 917
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs NSE:GLAND: 284.39
Gland Pharma's Days Inventory
declined
from Mar. 2025 (315.15) to Mar. 2026 (269.10).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Gland Pharma's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.34.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Gland Pharma's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.00.
Gland Pharma (NSE:GLAND) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Gland Pharma's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Gland Pharma's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Gland Pharma Days Inventory Related Terms
Gland Pharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Gland Pharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Gland Pharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gland Pharma (NSE:GLAND) has a Days Inventory of 269.10 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Gland Pharma and its competitors. This is near median its historical median of 283.29. Over the past decade, Gland Pharma's Days Inventory has ranged from 212.92 to 339.02. According to the industry distribution chart, Gland Pharma ranks #751 out of 917 companies in the Drug Manufacturers industry, placing it in the top 81.9%.
Is Gland Pharma's Days Inventory too high?
Gland Pharma's current Days Inventory of 269.10 is near median its 10-year median of 283.29. Over the past 10 years, this metric has ranged from a low of 212.92 to a high of 339.02. The Drug Manufacturers industry median Days Inventory is 164.48. Gland Pharma's value of 269.10 is 63.6% above this industry median. Based on the distribution chart, Gland Pharma ranks #751 out of 917 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gland Pharma has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #751 out of 917 companies for Days Inventory. This places Gland Pharma in the lower half of its industry. The industry median Days Inventory is 164.48. Gland Pharma's value of 269.10 is 63.6% above this benchmark. Historically, Gland Pharma's own Days Inventory has ranged from 212.92 to 339.02 over the past decade. While the company's 10-year median is 283.29 vs. the industry median of 164.48, Gland Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 917 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gland Pharma's current Days Inventory of 269.10 is 63.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current Days Inventory is 269.10, which is near median its own 10-year median of 283.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,129.62, compared to a current price of ₹2,495.00 — trading 17.2% above its estimated fair value. The current Days Inventory is 269.10, which is near median its 10-year median of 283.29 and 63.6% above the Drug Manufacturers industry median of 164.48. Gland Pharma's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Days Inventory is 269.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,495.00 is trading 17.2% above its estimated GF Value™ of ₹2,129.62.
GuruFocus considers Gland Pharma to be Modestly Overvalued.
Key valuation signals for NSE:GLAND:
Days Inventory: 269.10 (near median its 10-year median of 283.29)
GF Value™: ₹2,129.62 vs. price of ₹2,495.00 (17.2% above fair value)
Industry Position: 63.6% above the Drug Manufacturers median (#751 of 917)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
83GF Score
Get the complete analysis for NSE:GLAND
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
